JP2024521806A - 合成Ｃａｓタンパク質 - Google Patents

合成Ｃａｓタンパク質 Download PDF

Info

Publication number
JP2024521806A
JP2024521806A JP2023573060A JP2023573060A JP2024521806A JP 2024521806 A JP2024521806 A JP 2024521806A JP 2023573060 A JP2023573060 A JP 2023573060A JP 2023573060 A JP2023573060 A JP 2023573060A JP 2024521806 A JP2024521806 A JP 2024521806A
Authority
JP
Japan
Prior art keywords
cas
sequences
nuclease
ancestral
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521806A5 (https=
Inventor
ペレス―ヒメネス，ラウール
アロンソ―レルマ，ボルハ
Original Assignee
アソシエーション セントロ デ インベスティゲイション クーペレイティヴァ アン ナノシエンシアス “シーアイシー ナノグネ”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2107671.6A external-priority patent/GB202107671D0/en
Application filed by アソシエーション セントロ デ インベスティゲイション クーペレイティヴァ アン ナノシエンシアス “シーアイシー ナノグネ” filed Critical アソシエーション セントロ デ インベスティゲイション クーペレイティヴァ アン ナノシエンシアス “シーアイシー ナノグネ”
Publication of JP2024521806A publication Critical patent/JP2024521806A/ja
Publication of JP2024521806A5 publication Critical patent/JP2024521806A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B10/00—ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2023573060A 2021-05-25 2022-05-25 合成Ｃａｓタンパク質 Pending JP2024521806A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21382474 2021-05-25
EP21382474.1 2021-05-25
GBGB2107671.6A GB202107671D0 (en) 2021-05-28 2021-05-28 Synthetic cas proteins
GB2107671.6 2021-05-28
EP22165690 2022-03-30
EP22165690.3 2022-03-30
PCT/EP2022/064307 WO2022248607A2 (en) 2021-05-25 2022-05-25 Synthetic cas proteins

Publications (2)

Publication Number Publication Date
JP2024521806A true JP2024521806A (ja) 2024-06-04
JP2024521806A5 JP2024521806A5 (https=) 2025-06-02

Family

ID=82319633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573060A Pending JP2024521806A (ja) 2021-05-25 2022-05-25 合成Ｃａｓタンパク質

Country Status (4)

Country Link
US (1) US20240240165A1 (https=)
EP (1) EP4347808A2 (https=)
JP (1) JP2024521806A (https=)
WO (1) WO2022248607A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024236558A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025061765A1 (en) 2023-09-19 2025-03-27 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Synthetic cas proteins
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150329555A1 (en) * 2014-05-19 2015-11-19 Pfizer Inc. Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr
US20150376586A1 (en) * 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
WO2017070633A2 (en) * 2015-10-23 2017-04-27 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
WO2017096041A1 (en) * 2015-12-02 2017-06-08 The Regents Of The University Of California Compositions and methods for modifying a target nucleic acid
WO2017123609A1 (en) * 2016-01-12 2017-07-20 The Regents Of The University Of California Compositions and methods for enhanced genome editing
WO2017136325A1 (en) * 2016-02-01 2017-08-10 Ecolab Usa Inc. Solid laundry detergent for restaurant soils
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
WO2018071868A1 (en) * 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
WO2019123429A1 (en) * 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a
WO2019139645A2 (en) * 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019161251A1 (en) * 2018-02-15 2019-08-22 The Broad Institute, Inc. Cell data recorders and uses thereof
US20190264232A1 (en) * 2018-02-23 2019-08-29 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
WO2021087246A1 (en) * 2019-10-31 2021-05-06 Inari Agriculture, Inc. Base-editing systems
WO2021084533A1 (en) * 2019-10-28 2021-05-06 Targetgene Biotechnologies Ltd Pam-reduced and pam-abolished cas derivatives compositions and uses thereof in genetic modulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7044373B2 (ja) 2015-07-15 2022-03-30 ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
WO2020086908A1 (en) * 2018-10-24 2020-04-30 The Broad Institute, Inc. Constructs for improved hdr-dependent genomic editing

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190321382A1 (en) * 2014-05-19 2019-10-24 Pfizer Inc. Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr
US20150329555A1 (en) * 2014-05-19 2015-11-19 Pfizer Inc. Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr
US20150376586A1 (en) * 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
WO2017070633A2 (en) * 2015-10-23 2017-04-27 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
WO2017096041A1 (en) * 2015-12-02 2017-06-08 The Regents Of The University Of California Compositions and methods for modifying a target nucleic acid
WO2017123609A1 (en) * 2016-01-12 2017-07-20 The Regents Of The University Of California Compositions and methods for enhanced genome editing
WO2017136325A1 (en) * 2016-02-01 2017-08-10 Ecolab Usa Inc. Solid laundry detergent for restaurant soils
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
WO2018071868A1 (en) * 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
WO2019139645A2 (en) * 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019123429A1 (en) * 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a
WO2019161251A1 (en) * 2018-02-15 2019-08-22 The Broad Institute, Inc. Cell data recorders and uses thereof
US20190264232A1 (en) * 2018-02-23 2019-08-29 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
WO2021084533A1 (en) * 2019-10-28 2021-05-06 Targetgene Biotechnologies Ltd Pam-reduced and pam-abolished cas derivatives compositions and uses thereof in genetic modulation
WO2021087246A1 (en) * 2019-10-31 2021-05-06 Inari Agriculture, Inc. Base-editing systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WALTON T. RUSSELL ET AL.: "Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants", SCIENCE, vol. 368, JPN6026009677, 17 April 2020 (2020-04-17), pages 290 - 296, ISSN: 0005813285 *

Also Published As

Publication number Publication date
WO2022248607A3 (en) 2023-01-05
WO2022248607A2 (en) 2022-12-01
US20240240165A1 (en) 2024-07-18
EP4347808A2 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
AU2022246445B2 (en) Variants of Cpf1 (Cas12a) with altered PAM specificity
JP7761294B2 (ja) 遺伝子編集における非意図的な変異の阻害
JP2024521806A (ja) 合成Ｃａｓタンパク質
US20220364067A1 (en) Base editing enzymes
AU2021201354A1 (en) Nuclease profiling system
KR102773642B1 (ko) 열 안정성 cas9 뉴클레아제
CN114875012B (zh) 工程化的CRISPR-Cas9核酸酶
US9926546B2 (en) Engineered CRISPR-Cas9 nucleases
US12503710B2 (en) Base editing enzymes
AU2017204909A1 (en) Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
JP2024541402A (ja) エンドヌクレアーゼ系
US10920272B2 (en) High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro
KR20220084322A (ko) 세포에서 하나 이상의 표적-특이적인 프로그램 가능한 뉴클레아제의 오프-타겟 활성을 프로파일링하는 진정한 편향되지 않은 시험관내 분석(abnoba-seq)
GB2700205A (en) Base editing enzymes
CN117693585A (zh) Ii类v型crispr系统
CN118265783A (zh) 核酸内切酶系统
CN117858944A (zh) 合成cas蛋白
US12421527B2 (en) Argonaute proteins from prokaryotes and applications thereof
Keiser Functional characterization of the newly discovered type V CRISPR-Cas protein Cas12a2
Adorno Engineering Controllable And Efficient Base Editors By Targeted Manipulation Of Dna Deaminases
BR122024021834A2 (pt) Proteína crispr de prevotella e francisella 1 (cpf1) isolada lachnospiraceae bacterium nd2006 (lbcpf1), proteína de fusão, ácido nucleico isolado, vetor, célula hospedeira, método in vitro de alteração do genoma de uma célula, método in vitro de alteração de uma molécula de dna de fita dupla (dsdna), método de detecção de um ssdna ou dsdna-alvo in vitro em uma amostra

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310